sunitinib

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Well-differentiated Pancreatic Neuroendocrine Tumor

Conditions

Well-differentiated Pancreatic Neuroendocrine Tumor

Trial Timeline

Jun 6, 2012 → Jul 26, 2018

NCT ID

NCT01525550

About sunitinib

sunitinib is a approved stage product being developed by Pfizer for Well-differentiated Pancreatic Neuroendocrine Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01525550. Target conditions include Well-differentiated Pancreatic Neuroendocrine Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05745142	Pre-clinical	Completed	Feb 23, 2023	Feb 23, 2023	Carcinoma, Renal Cell
NCT04115189	Pre-clinical	Completed	Dec 13, 2019	Dec 2, 2020	Metastatic Renal Cell Carcinoma ( mRCC)
NCT04175262	Pre-clinical	Completed	Oct 31, 2019	Mar 9, 2020	Metastatic Renal Cell Carcinoma (mRCC)
NCT04076787	Pre-clinical	Completed	Sep 1, 2018	Sep 2, 2018	Metastatic Renal Cell Carcinoma
NCT03592199	Phase 2	UNKNOWN	Dec 11, 2017	Dec 11, 2022	Clear Cell Renal Cell Carcinoma
NCT03140176	Pre-clinical	Terminated	Aug 15, 2017	Jan 22, 2022	Metastatic Renal Cell Carcinoma
NCT03066427	Phase 2	Completed	May 10, 2017	Sep 22, 2020	Clear Cell Renal Carcinoma
NCT02713763	Phase 2	Completed	Feb 14, 2017	Oct 23, 2019	Pancreatic Neuroendocrine Tumour Metastatic
NCT02689167	Phase 2	UNKNOWN	Feb 19, 2016	Feb 1, 2024	Kidney Neoplasms
NCT02282059	Pre-clinical	Completed	Dec 12, 2014	Dec 12, 2022	Pancreatic Neuroendocrine Tumors
NCT02060370	Phase 2	Completed	Aug 1, 2014	Jan 2, 2019	Genitourinary Cancer
NCT01525550	Approved	Completed	Jun 6, 2012	Jul 26, 2018	Well-differentiated Pancreatic Neuroendocrine Tumor
NCT01499121	Phase 2	Completed	May 1, 2012	Sep 30, 2017	Clear Cell, Metastatic Renal Cell Carcinoma
NCT01286896	Phase 1	Completed	Apr 11, 2011	Dec 27, 2011	Malignant Solid Tumour
NCT01070186	Phase 2	Withdrawn	Oct 1, 2010	—	Renal Cell Carcinoma
NCT01121562	Phase 2	Completed	Jul 1, 2010	Nov 1, 2013	Pancreatic Neuroendocrine Tumors
NCT01033981	Pre-clinical	Terminated	May 1, 2010	Feb 1, 2011	Metastatic Renal Cell Carcinoma
NCT01054911	Pre-clinical	Terminated	Oct 1, 2009	Sep 1, 2015	Tumor
NCT01042795	Phase 2	Terminated	Sep 1, 2009	Jan 1, 2013	Urothelial Carcinoma
NCT01069770	Phase 2	UNKNOWN	Jul 1, 2009	Jun 1, 2012	Clear Cell Renal Cell Carcinoma

Competing Products

2 competing products in Well-differentiated Pancreatic Neuroendocrine Tumor

See all competitors

Product	Company	Stage	Hype Score
PDR001	Novartis	Phase 2	35
INCMGA00012 + Palbociclib	Incyte	Phase 2	36